Urea-to-Albumin Ratio and In-Hospital Mortality in Severe Pneumonia Patients

Objective. The urea-to-albumin ratio (UAR), as a new marker of the systemic inflammatory response, is associated with the mortality in pneumonia patients. However, the association between the UAR and in-hospital mortality in severe pneumonia (SP) has received little attention. Methods. In this single-center retrospective cohort study, 212 SP patients in intensive care unit (ICU) from June 1, 2016, to June 1st, 2020, with baseline UAR were enrolled. The primary outcome was in-hospital mortality. The association of UAR with in-hospital mortality was assessed using a multivariable-adjusted Cox model. Results. Of 212 patients, the median age was 73.0 (61.0, 82.8) years, 70.8% of patients were male, and the APACHE II score was 20.0 (16.0, 26.0). During the hospital period, 101 (47.6%) patients died. In-hospital mortality rates for the lower and higher UAR were 16 (27.6%) and 85 (55.2%), respectively P < 0.001 . Kaplan–Meier analysis revealed that survival rates were significantly different between the two groups (log rank = 13.71, P < 0.001 ). After adjusted for confounding factors, the higher UAR group was significantly associated with a hazard ratio (HR) for in-hospital mortality of 2.234 (95% confidence interval: 1.146–4.356, P = 0.018 ). Besides, this pattern persisted in subgroup analyses considering sex (HR = 9.380; 95% CI: 2.248–39.138; P = 0.002 ). Conclusions. Higher UAR levels at the commencement of admission to ICU may be independently associated with increased in-hospital mortality in SP patients.

Download Full-text

Influence of fluid balance on the prognosis of patients with sepsis

BMC Anesthesiology ◽

10.1186/s12871-021-01489-1 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Luming Zhang ◽

Fengshuo Xu ◽

Shaojin Li ◽

Xiaoyu Zheng ◽

Shuai Zheng ◽

...

Keyword(s):

Hospital Mortality ◽

Fluid Balance ◽

Primary Outcome ◽

Cox Regression ◽

Cox Model ◽

Research Database ◽

Kaplan Meier ◽

Survival Difference ◽

Positive Balance ◽

Survival Differences

Abstract Background Early and timely fluid treatment or resuscitation are the basic measures for the active treatment of sepsis. Our aim is to further explore the relationship between fluid balance and prognosis in patients with sepsis on a daily basis for 5 days. Methods Sepsis patients in eICU Collaborative Research Database were divided into the negative balance group (NB/−) and the positive balance group (PB/+) according to daily fluid balance. The primary outcome was in-hospital mortality. Survival differences between the groups were analyzed by using Cox regression. Then dose-response relationship between fluid balance and in-hospital mortality was studied using restricted cubic splines (RCSs). Furthermore, patients with fluid balance data for the previous three consecutive days were selected and divided into eight groups (“+/+/+”, “+/+/−”, “+/ −/−”, “+/ −/+”, “−/ −/−”, “−/ −/+”, “−/+/+”, and “−/+/−”). Kaplan–Meier curves and Cox regression were used to show the survival difference between groups. Results Our study, which included 19,557 patients in a multicenter database, showed that positive fluid balances on days 1, 2, and 3 after sepsis diagnosis were associated with poor prognosis with the HRs of 1.29 (1.20,1.40), 1.13 (1.01,1.27), and 1.25 (1.08,1.44), respectively, while the fluid balance on days 4 and 5 had no effect on the primary outcome. Then RCSs showed an overall trend that the risk of in-hospital mortality on days 1, 2, and 3 increased with increasing fluid balance. For three consecutive days of fluid balance, we studied 9205 patients and Kaplan–Meier curves revealed survival differences among patients in the eight groups. The cox model demonstrated that compared with the “+/+/+” group, the “+/ −/−”, “−/ −/−”, “−/ −/+”, “−/+/+”, and “−/+/−” groups had a lower risk of in-hospital mortality, with HRs of 0.65 (0.45,0.93), 0.72 (0.60,0.86), 0.63 (0.43,0.93), 0.69 (0.48,0.98), and 0.63 (0.42,0.96), respectively. Conclusions In patients with sepsis, positive fluid balance on days 1, 2, and 3 was associated with adverse outcomes. For patients with fluid balance for three consecutive days, the “+/−/−”, “−/ −/−”, “−/−/+”, “−/+/+”, and “−/+/−” groups were less likely to die in hospital than the “+/+/+” group.

Download Full-text

High Mean Platelet Volume Associates with In-Hospital Mortality in Severe Pneumonia Patients

Mediators of Inflammation ◽

10.1155/2020/8720535 ◽

2020 ◽

Vol 2020 ◽

pp. 1-9 ◽

Cited By ~ 1

Author(s):

Jieru Chen ◽

Yihao Li ◽

Yingsi Zeng ◽

Yu Tian ◽

Yueqiang Wen ◽

...

Keyword(s):

Hospital Mortality ◽

Mean Platelet Volume ◽

Cox Regression ◽

Cox Model ◽

Predictive Ability ◽

Severe Pneumonia ◽

Platelet Volume ◽

Kaplan Meier ◽

Increased Risk ◽

The Relationship

Background. Although mean platelet volume (MPV) appears to be associated with poor outcome of pneumonia, the relationship between MPV and in-hospital mortality is unclear in severe pneumonia (SP) patients. Methods. In this retrospective cohort study, 115 SP patients from June 1st, 2016, to September 29th, 2019, were included and divided into two groups. The primary outcome was in-hospital mortality. The receiver operating characteristic (ROC) curve was performed to assess the predictive ability for in-hospital mortality. Kaplan-Meier cumulative incidence curves were applied to observe the incidence of mortality. Multivariable Cox regression analyses were used to evaluate the hazard ratios (HRs). Besides, a formal test for interaction was investigated to analyze the relationship between MPV and sex. Results. During the course of hospitalization, 63 cases of mortality were recorded. ROC analysis suggested that MPV had a modest power for predicting in-hospital mortality (AUC=0.723, 95% CI: 0.628-0.818, P<0.001). Yet the cutoff value of MPV was 10.5 (sensitivity=73.02%; specificity=73.08%). Compared to the low-MPV group, the high-MPV group had significantly increased in-hospital mortality (log-rank test=13.501, P<0.001), while the adjusted Cox model indicated that the high-MPV group was associated with an elevated risk of in-hospital mortality (HR: 2.267, 95% CI: 1.166-4.406, P=0.016). Moreover, analyses of in-hospital mortality suggested a significant interaction between optimal MPV level and sex (P=0.011). In a multivariate Cox model which included females only, a high MPV level was associated with increased risk of in-hospital mortality (HR: 11.387, 95% CI: 1.767-73.380, P=0.011). Conclusion. High MPV level is an independent risk factor for in-hospital mortality in patients with SP.

Download Full-text

Associations of Volume and Thyroidectomy Outcomes

Otolaryngology ◽

10.1177/0194599816634627 ◽

2016 ◽

Vol 155 (1) ◽

pp. 65-75 ◽

Cited By ~ 20

Author(s):

Tsung-Jung Liang ◽

Shiuh-Inn Liu ◽

King-Tong Mok ◽

Hon-Yi Shi

Keyword(s):

Hospital Mortality ◽

Meta Analysis ◽

Relevant Literature ◽

Survival Rates ◽

High Volume ◽

Mortality Rates ◽

Surgeon Volume ◽

The Mean ◽

Low Volume ◽

Mean Cost

Objective This study explored how different hospital volumes and surgeon volumes affect thyroidectomy outcomes in terms of length of stay (LOS), costs, and in-hospital mortality. Data Sources MEDLINE and EMBASE databases. Review Methods This study retrospectively analyzed a cohort of 125,037 thyroidectomy patients treated at Taiwan hospitals from 1996 to 2010. Relationships between hospital/surgeon volume and patient outcomes were retrospectively analyzed by propensity score matching. In conjunction with the retrospective study, a systematic review and meta-analysis of the relevant literature also were performed. Results The mean LOS for all thyroidectomies performed during the study period was 3.3 days, and the mean cost was $1193.5. Both high-volume hospitals and high-volume surgeons were associated with significantly shorter LOS and lower costs compared with their low-volume counterparts ( P < .001). Different volume groups had similar in-hospital mortality rates. The meta-analysis results consistently showed that the benefits of high-volume hospitals/surgeons are reduced LOS and costs. However, low in-hospital mortality rates were associated with high-volume surgeons but not with high-volume hospitals. Conclusions This meta-analysis showed that patients who received thyroidectomies performed by high-volume hospitals and surgeons had shorter LOS and lower costs compared with those treated by low-volume hospitals and surgeons. In addition, in-hospital survival rates were better in patients treated by high-volume surgeons. Further research is needed to define the learning curve for thyroidectomy and to clarify how hospital volume and surgeon volume affect its success rate.

Download Full-text

Early Experience With Neutralizing Monoclonal Antibody Therapy For COVID-19

10.1101/2021.04.09.21255219 ◽

2021 ◽

Author(s):

Mark Jarrett ◽

Warren B. Licht ◽

Kevin Bock ◽

Zenobia Brown ◽

Jamie S. Hirsch ◽

...

Keyword(s):

Monoclonal Antibody ◽

High Risk ◽

Hospital Mortality ◽

Primary Outcome ◽

Cox Model ◽

Adult Patients ◽

Infusion Therapy ◽

Probability Weighting ◽

Inverse Probability ◽

Neutralizing Monoclonal Antibody

ABSTRACTImportanceNeutralizing monoclonal antibody (MAB) therapies may benefit patients with mild to moderate COVID-19 at high risk for progressing to severe COVID-19 and/or hospitalization. Studies documenting approaches to deliver MAB infusions as well as demonstrating their efficacy are lacking.ObjectiveWe describe our experience and patient outcomes of almost 3,000 patients who received MAB infusion therapy at Northwell Health, a large integrated health care system in New York.Design, Setting, and ParticipantsThis is a descriptive study of adult patients who received MAB therapy between November 20, 2020, to January 31, 2021, and a retrospective cohort survival analysis comparing patients who received MAB therapy prior to admission versus those who did not. A multivariable Cox model with inverse probability weighting according to the propensity score including covariates (sociodemographic, comorbidities, and presenting vital signs) was used.Main outcomes and measuresThe primary outcome was in-hospital mortality; additional evaluations included ED utilization and hospitalization within 28 days of a positive COVID-19 test for patients who received MAB therapy.ResultsDuring the study period, 2818 adult patients received MAB infusion. Following therapy and within 28 days of COVID-19 test, 123 patients (4.4%) presented to the ED and were released and 145 patients (5.1%) were hospitalized. These 145 patients were compared with 200 controls who were eligible for but did not receive MAB therapy, and were hospitalized. In the MAB group, 16 (11%) patients met the primary outcome of in-hospital mortality, versus 21 (10.5%) in the control group. In an unadjusted Cox model, the hazard ratio (HR) for time to in-hospital mortality for the MAB group was 1.38 (95% confidence interval [95% CI] 0.696-2.719). Models adjusting for demographics (HR 1.1, 95% CI 0.53-2.23), demographics and Charlson Comorbidity Index (CCI) (HR 1.22, 95% CI 0.573-2.59), and with inverse probability weighting according to propensity scores (HR 1.19, 95% CI 0.619-2.29) did not demonstrate significance. The hospitalization rate was 4.4% for patients who received MAB therapy within 0-4 days, 5% within 5-7 days, and 6.1% within ≥8 days of symptom onset (p-value = 0.15).Conclusions and relevanceEstablishing the capability to provide neutralizing MAB infusion therapy requires significant planning and coordination. While this therapy may be an important treatment option for early mild to moderate COVID-19 in high-risk patients, further investigations are needed to define the optimal timing of MAB treatment in order to reduce hospitalization and mortality.

Download Full-text

Abstract 16632: Clinical Characteristics and In-Hospital Outcomes of Covid-19 Patients With Ecg St Segment Elevation: A System Wide Analysis

Circulation ◽

10.1161/circ.142.suppl_3.16632 ◽

2020 ◽

Vol 142 (Suppl_3) ◽

Author(s):

Avneet SINGH ◽

Perwaiz Meraj ◽

Arvind Reddy ◽

Eitezaz Mahmood ◽

Ibrahim Ali ◽

...

Keyword(s):

New York ◽

Hospital Mortality ◽

Clinical Characteristics ◽

Survival Rates ◽

Female Gender ◽

Stepwise Logistic Regression ◽

Stepwise Logistic Regression Analysis ◽

St Segment Elevation ◽

Kaplan Meier ◽

St Segment

Myocardial injury is seen in approximately 20% of COVID-19 patients and ST elevation myocardial infarction may be the presenting clinical manifestation. Recent data suggest that the ST-segment elevation (STE) may be due to myopericarditis. We assessed the clinical characteristics, electrocardiographic patterns, incidence, management and outcomes of COVID-19 pts with STE. Methods: We analyzed 23,406 ECGs (10,018 pts) admitted to 13 New York City area hospitals between March 1 and April 30, 2020. Results: After manual adjudication, 51 (0.5%) had focal STE, 22 (0.2%) had diffuse STE and 9,945 did not have STE. Baseline clinical characteristics were similar among the three groups, albeit a higher percentage of pts with low ejection fraction in the diffuse STE group. Cardiac catheterization was performed on 10 pts. Three pts did not have obstructive disease. Pts with focal STE were more likely to require inotropes and die during index hospitalization. Kaplan-Meier estimated overall survival rates were 31%, 33% and 6% in patients without STE, focal and diffuse STE, respectively (p < 0.0001) (Figure). By stepwise logistic regression analysis, focal STE was the strongest predictor of death (OR=7.0; CI 3.8-13.0, p<0 .0001) followed by age > 65 years (OR=3.5; CI 3.1-3.9; p<0.0001) and diffuse STE (OR=2.9; CI 1.1-7.2; p<0.0001). Female gender was associated with a decreased risk (OR 0.72; CI, 0.65-0.79; p<0.0001). Conclusions: In this large retrospective analysis of 10,018 COVID-19 pts, we observed that: 1) a very small percentage (0.7%) presented with STE; 2) 70% had focal STE and 30% had diffuse STE; 3) a minority underwent coronary angiography; 4) in-hospital mortality rates were very high for pts with STE, and even more so for those with focal STE (63% vs 46%) and; 5) focal STE was the strongest predictor of in-hospital mortality and female gender was a predictor of survival.

Download Full-text

Neutrophil Percentage to Albumin Ratio Was Associated with Clinical Outcomes in Coronary Care Unit Patients

10.21203/rs.3.rs-729333/v1 ◽

2021 ◽

Author(s):

Chenghui Cai ◽

Tienan Sun ◽

Fang Zhao ◽

Jun Ma ◽

Xin Pei ◽

...

Keyword(s):

Acute Kidney Injury ◽

Hospital Mortality ◽

Coronary Care Unit ◽

Kidney Injury ◽

Roc Curves ◽

Albumin Ratio ◽

Cumulative Survival ◽

Kaplan Meier ◽

Neutrophil Percentage ◽

Coronary Care

Abstract Background: Neutrophil percentage to albumin ratio (NPAR) was proved to be correlated with the prognosis of a variety of diseases. The purpose of this study was to explore the effect of NPAR on the prognosis of coronary care unit (CCU) dpatients.Method: All data of this study was extracted from Medical Information Mart for Intensive Care III (MIMIC-III, version1.4) database. All patients were divided into four groups according to NPAR quartiles. Primary outcome was in-hospital mortality and secondary outcomes were 30-day mortality, 365-day mortality, length of CCU stay, length of hospital stay, acute kidney injury, renal replacement therapy. Multivariable binary logistic regression analysis was performed to confirm the independent effect of NPAR. Subgroup analysis was used to determine the effect of NPAR on in-hospital mortality in different subgroups. Receiver-operating characteristic (ROC) curves were applied to evaluate the ability of NPAR to predict in-hospital mortality. Kaplan–Meier curves were built to compare cumulative survival of different groups.Result: 2364 CCU patients were enrolled in this study. In-hospital mortality rate increased significantly as NPAR quartiles increased (P < 0.001). In multivariable logistic regression, NPAR was proved to be independently associated with in-hospital mortality (Quartile 4 vs Quartile 1: OR, 95% CI: 1.80, 1.19-2.72, P=0.005, P for trend = 0.001). Moderate ability of NPAR to predict in-hospital mortality was demonstrated through ROC curves, the AUC of NPAR was 0.653 (P<0.001), which is better than PLR (P<0.001), neutrophil (P<0.001) but lower than SOFA(P=0.046) and SAPS II (P<0.001). Subgroup analysis did not find obvious interaction in most subgroups. Moreover, Kaplan-Meier curves showed that as NPAR quartiles increased, 30-day (Log rank, P<0.001) and 365-day (Log rank, P<0.001) cumulative survival decreased significantly. NPAR was also proved to be independently associated with acute kidney injury (Quartile 4 vs Quartile 1: OR, 95% CI: 1.57, 1.19-2.07, P=0.002, P for trend = 0.001). Length of CCU and hospital stay were prolonged significantly in higher NPAR quartiles.Conclusion: NPAR was an independent risk factor of in-hospital mortality in CCU patients and had a moderate ability to predict in-hospital mortality.

Download Full-text

Urea to Albumin Ratio Is an Independent Predictor of In-Hospital Mortality in Patients With Severe Pneumonia: A Retrospective Cohort Study

10.21203/rs.3.rs-510525/v1 ◽

2021 ◽

Author(s):

Yu Tian ◽

Yihao Li ◽

Jieru Chen ◽

Zixin Jiang

Keyword(s):

Hospital Mortality ◽

Cox Regression ◽

Interaction Analysis ◽

Severe Pneumonia ◽

Major Complication ◽

Albumin Ratio ◽

Mortality And Morbidity ◽

System Disease ◽

Cox Analysis ◽

High Level

Abstract Background: Severe pneumonia (SP) is a major complication of respiratory system disease that is associated with high mortality and morbidity. Our objective was to identify risk factors predictive of SP patients and its mortality in intensive care unit (ICU).Methods: We conducted a single-center retrospective observational study involving 212 patients with SP in ICU from June 1st, 2016 to June 1st, 2020. The receiver operating characteristic (ROC) curve was constructed to assess the predictive significance of urea to albumin ratio (U/A). Kaplan-Meier survival curves were plotted with log-rank tests to compare survival of patients with different value of U/A. Multivariate COX regression models were used to calculate the adjusted hazard ratios (HR). Additionally, interaction analysis showed the association between U/A and in-hospital mortality was influenced by sex. Primary outcome was in-hospital mortality.Results: A total of 212 patients were enrolled in the analysis. In the hospital, 101 (47.6%) patients had died. ROC analysis showed that the current cut-off of 0.2555 had a sensitivity of84.2% for in-hospital mortality (AUC = 0.63, 95%CI: 0.55-0.70,P = 0.001). The multivariate COX analysis showed that the incidence of death was higher with the higher U/A group than the lower group (HR: 2.234, 95%CI: 1.146-4.356, P = 0.018).Besides, this pattern persisted in subgroup analyses considering sex. (HR: 9.380, 95%CI: 2.248-39.138, P = 0.002)Conclusions: A high level of U/A is an independent risk factor for in-hospital mortality in patients with SP.

Download Full-text

Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study.

Blood ◽

10.1182/blood.v110.11.817.817 ◽

2007 ◽

Vol 110 (11) ◽

pp. 817-817 ◽

Cited By ~ 55

Author(s):

Pierre Fenaux ◽

G.J. Mufti ◽

V. Santini ◽

C. Finelli ◽

A. Giagounidis ◽

...

Keyword(s):

Cox Model ◽

Survival Rates ◽

Prospective Trial ◽

Safety Data ◽

Best Supportive Care ◽

Phase Iii ◽

First Line Therapy ◽

Kaplan Meier ◽

Phase Iii Study ◽

Central Pathology

Abstract Background: A previous CALGB trial (JCO2002;20:2429) showed a positive OS trend with AZA vs best supportive care (BSC) in MDS. The objective of this Phase III, international, multicenter, randomized, prospective trial was to demonstrate the superiority of AZA + BSC for prolonging OS vs CCR + BSC. Design: Higher-risk MDS patients (pts), FAB-defined as RAEB, RAEB-T, or CMML (10–29% marrow blasts) with an IPSS of Int-2 or High by central pathology/cytogenetic review, were enrolled. Before randomization, investigators preselected pts to 1 of 3 CCR: BSC only (transfusions, antibiotics, and G-CSF for neutropenic infection); low-dose ara-C (LDAC, 20 mg/m2/d x 14d, q 28d); or standard chemotherapy (Std CT: conventional induction/consolidation). Pts were stratified by FAB/IPSS and randomized to AZA (75 mg/m2/d x 7d, q 28d) or CCR. This trial did not allow erythropoietin. All analyses used the ITT population. Results: In all, 358 pts (70% male), were randomized at 79 sites to AZA (N=179) or CCR (N=179): BSC only (N=105, 59%), LDAC (N=49, 27%), or Std CT (N=25, 14%). Median age was 69 yrs (38–88) and per treatment (TX): AZA (69 yrs); BSC only (70 yrs); LDAC (71 yrs); and Std CT (65 yrs). The AZA and CCR groups were comparable for baseline (BL) parameters. At BL, 95% of pts were higher risk: RAEB (58%), RAEB-T/WHO AML (34%), CMML (3%), and other (5%). By IPSS, 87% were higher risk: Int-2 (40%), High (47%), and 13% indeterminate/other. AZA was administered for a median of 9 cycles; LDAC for 4 cycles. Median followup for the OS analysis was 21.1 months (mo). AZA demonstrated statistically superior OS vs CCR (stratified log-rank p=0.0001). AZA showed a median Kaplan-Meier (KM) OS time of 24.4 mo vs 15 mo with CCR (Figure). The hazard ratio (HR, Cox Model) was 0.58 (95% CI: 0.43, 0.77) for a 74% OS improvement. At 2 yrs, there was a 2-fold OS advantage: AZA (51%) vs CCR (26%), 95% CI: 13, 36%, p<0.0001. Differences in OS KM medians (HR; log-rank p) between AZA and BSC, LDAC, and Std CT, respectively, were 12.9 mo (0.55; p=0.0003), 9.1 mo (0.60; p=0.016), and 8.7 mo (0.69; p=0.19). Median OS per IPSS cytogenetic subgroup showed similar results (Table). The 1, 2, and 3-mo survival rates did not differ between AZA and BSC only (p>0.20). AZA was well tolerated with safety data consistent with previous reports. Conclusion: These data confirm and extend previous CALGB findings. This AZA trial is the first MDS clinical study to demonstrate a significant OS advantage, thus altering the natural disease course. AZA should now be considered first-line therapy for higher-risk MDS pts. OS Analyses per IPSS Cytogenetic Group Group % (n/N) Pts AZA Median (Months) CCR Median (Months) HR (95%CI) Log-rank p Good 46 (166/358) Not reached 17.1 0.61 (0.39, 0.96) 0.030 Intermediate 21 (76/358) 26.3 17.0 0.43 (0.21, 0.88) 0.017 Poor 28 (100/358) 17.2 6.0 0.52 (0.32, 0.87) 0.011 Figure Figure

Download Full-text

Epidemiology and survival analyses of 333 adult glioma patients from Eastern Algeria (2008-2016)

African Health Sciences ◽

10.4314/ahs.v20i3.29 ◽

2020 ◽

Vol 20 (3) ◽

pp. 1250-1258

Author(s):

Sabrina Touati ◽

Rachid Djekkoun ◽

Mohamed El-Hadef El-Okki ◽

Dalila Satta

Keyword(s):

Cox Model ◽

Survival Rates ◽

University Hospital ◽

Prognosis Factors ◽

Chi Square ◽

Oncological Treatment ◽

Kaplan Meier ◽

Chi Square Test ◽

The Mean ◽

Eastern Algeria

Background: Gliomas are a relatively rare group of tumors with a poor prognosis. We aimed to describe and analyze the clinical characteristics and survival of patients with glioma tumors of Eastern Algeria. Methods: A retrospective study was conducted at the University Hospital of Constantine. Medical records of patients enrolled between January 2008 and October 2016 were consulted. Demographic characteristics, clinical data, treatment strategy and dates of last follow-up or death were collected. Chi-square test was used for checking associations, Kaplan- Meier methodology for estimating the survival, and the cox model for identifying prognosis factors. Results: A total of 333 patients composed our cohort. The mean age was 48.07 years, and men were 1.87 times more frequent than women. High grade tumors were mainly observed among adults and old adults and in supra-tentorial locations. More than half of the patients had a large resection and a curative protocol of oncological treatment (50.7% and 57%, re- spectively). The mean overall survival was 45.4 months, the median was 21.7 months, and survival rates at 1-, 2-, and 5-years were: 62.8%, 48.5% and 32.9% respectively. Age, histology, grade of malignancy and oncological treatment were the major prognosis factors. Conclusion: Our sample was relatively young with a higher survival compared to others. Keywords: Glioma; epidemiology; Algeria.

Download Full-text

Can C-Reactive Protein to Albumin Ratio Predict In-Hospital Death Rate Due to COVID-19 in Patients With Hypertension?

Angiology ◽

10.1177/00033197211012145 ◽

2021 ◽

pp. 000331972110121

Author(s):

Faysal Saylik ◽

Tayyar Akbulut ◽

Safak Kaya

Keyword(s):

Logistic Regression ◽

Regression Analysis ◽

Hospital Mortality ◽

Independent Predictor ◽

Hospital Death ◽

C Reactive Protein ◽

Albumin Ratio ◽

Cutoff Value ◽

Reactive Protein ◽

Kaplan Meier

Hypertension is one of the main morbidity and mortality risk factors in patients with coronavirus disease 2019 (COVID-19). We investigated the association between the C-reactive protein (CRP) to albumin ratio (CAR) and in-hospital mortality in patients with hypertensive COVID-19. A total of 176 patients with hypertension diagnosed with COVID-19 were included in this study. The CAR was compared between survivors and nonsurvivors. Logistic regression analysis was used to detect independent predictors of mortality due to COVID-19 in patients with hypertension. A cutoff value of CAR was obtained for predicting in-hospital death in patients with hypertensive COVID-19. Kaplan-Meier analysis was performed for survival analysis in the study population. The CAR values were significantly higher in nonsurvivors than in survivors with hypertension. Moreover, the CAR was an independent predictor of in-hospital death in patients with hypertensive COVID-19, as shown in multivariable logistic regression analysis. Receiver operating characteristic analysis yielded a cutoff value of 20.75 for the CAR for predicting in-hospital death in patients with hypertension. Kaplan-Meier curve analysis showed that patients with hypertensive COVID-19 with a CAR value of ≥20.75 had a higher incidence of in-hospital death. The CAR might be used as an independent predictor of in-hospital mortality in patients with hypertensive COVID-19.

Download Full-text